Topic: nonalcoholic steatohepatitis (NASH)
Now, Insitro is ready to share a little more—starting with a Gilead partnership worth $15 million upfront, but that could total more than $1 billion.
Gilead is hoping that adding a diabetes drug from Novo can help boost its ability to knock out fat in the liver.
As the International Liver Congress kicks off in Vienna, Big Biotech Gilead is one of the first players to reveal its NASH data.
The pair has been studying imeglimin, a new type of drug the partners say is the first clinical candidate in a new chemical class of oral agents.
Fatty liver disease biotech NGM Bio has got off a $107 million IPO, following in the footsteps of rival GenFit.
Already on the Euronext stock exchange, liver disease biotech GenFit has made the jump to the more lucrative Nasdaq with a $135 million IPO.
Israeli biotech Can-Fite missed the primary endpoint in a midstage test of its experimental late-stage liver cancer drug namodenoson.
The latest setback saw the Novartis-partnered liver disease drug fail to beat placebo in NASH patients, wiping another 50% off Conatus’ stock price.
It’s a pretty good news day for NGM Bio: Merck doubled down on its R&D pact, and it’s nabbed a Genentech executive to help run its trials.
Merck is extending its 2015 R&D pact with NGM Bio for a broad range of early-stage assets. It's also culling one therapy that didn't work out.